|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01093 CSPC PHARMA
Nominal 
5.330 -0.140 (-2.559%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Turnover | 16,284,282 | 1.268% | 16,080,412 | 15,610,026 | 13,822,275 | 12,589,597 |
| Cost of Sales | (4,629,735) | -4.399% | (4,842,773) | (4,271,542) | (3,297,610) | (3,152,244) |
| Gross Profit | 11,654,547 | 3.710% | 11,237,639 | 11,338,484 | 10,524,665 | 9,437,353 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | 24,273 | 295,863 | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (51,669) | 179.247% | (18,503) | 823 | 1,550 | 6,794 | |
| Profit / (Loss) before Taxation | 3,801,130 | 3.248% | 3,681,554 | 3,719,460 | 3,662,878 | 2,915,747 | |
| Taxation | (749,664) | 20.232% | (623,514) | (692,377) | (553,767) | (565,273) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (31,092) | -65.853% | (91,053) | (60,878) | (46,542) | (36,478) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,020,374 | 1.799% | 2,966,987 | 2,966,205 | 3,062,569 | 2,313,996 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Net Finance Costs / (Income) | (102,807) | -9.884% | (114,083) | (88,753) | (70,223) | (20,900) |
| Depreciation & Amortisation | 631,531 | 18.731% | 531,900 | 481,634 | 430,480 | 389,051 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| EPS (cts) | 25.510 | 2.244% | 24.950 | 24.890 | 25.620 | 19.360 |
| DPS (cts) | 14.648 | -- | 12.858 | 8.715 | 6.653 | 3.342 |
| Dividend Payout Ratio (%) | 57.423% | -- | 51.536% | 35.015% | 25.967% | 17.264% |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 2.930 | -- | 2.673 | 2.350 | 2.046 | 1.668 |
| Remarks: | Real time quote last updated: 06/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,020,374 |
| %Change | 1.799% |
| EPS / (LPS) | RMB 0.255 |
| NBV Per Share (¥) | RMB 2.930 |